Aptuit Announces Acquisition of Exquiron Biotech AG
News Apr 29, 2016
Aptuit, LLC has announced that it has acquired Exquiron Biotech AG to meet customer demand for fully integrated outsourced discovery services. Exquiron is a leading specialist Contract Research Organization dedicated to early phase drug discovery solutions.
Located near Basel, Switzerland, Exquiron offers industry leading expertise in assay development for hit finding and profiling purposes, high throughput screening, selectivity testing and hit characterization. These services are complemented by an extensive library collection of lead like compounds, as well as deep scientific knowledge in compound selection and Structure Activity Relationship (SAR) expansion across a broad range of targets in multiple therapeutic areas.
Dr. Jonathan Goldman, Chief Executive Officer of Aptuit stated, “Aptuit specializes in the discovery of small molecules across a wide range of therapeutic areas including neuroscience, oncology, infectious disease, inflammation, respiratory and others. The acquisition of Exquiron broadens our scientific excellence in advanced integrated discovery by incorporating capabilities in early discovery.
In particular, we are thrilled to enhance our hit identification, validation, and expansion services. We can now offer uninterrupted and very high quality delivery of a research program from target to high quality candidate nomination. We expect our customers to benefit from improved probability of candidate nomination, with reductions in time and cost.
Customers value our unique capabilities in integrated discovery and integrated development. We are delighted to combine our core scientific expertise in discovery with the early discovery capabilities of our Exquiron colleagues.”
Dr. Goldman explained that Aptuit’s best in class integrated discovery solutions are unique in the marketplace. “Our company is experiencing increased demand for integrated services from gene up to candidate nomination, and from candidate to IND. We are delighted to respond by expanding our capabilities”.
Dr. Stephan Fasler, CEO and founder of Exquiron added, “We are excited to join Aptuit, a highly respected leader in the discovery and development CRO sector. Our customers can now combine our expertise in assay development and high throughput screening with the ability to translate seamlessly to candidate nomination and IND filing. Exquiron and Aptuit share a culture and commitment to scientific excellence, making this a very good fit”.
Artificial Leaf Acts as a Mini Medicine FactoryNews
Using sunlight for sustainable and cheap production of, for example, medicines. The 'mini-factory' in the form of a leaf that was presented in 2016 showed that it is possible. Now researchers have come with an improved version: their 'mini-factory' is now able to keep production at the same level, irrespective of the variation in sunlight due to cloudiness or time of the day.READ MORE
Compound Offers Pain-relief of Opioids Without Addictive PropertiesNews
Researchers have engineered a new compound that animal tests suggest could offer the pain-relieving properties of opioids such as morphine and oxycodone without the risk of addiction.READ MORE
E. Coli’s Internal Bomb Offers Chink In ArmourNews
Bacteria's internal bomb, the so-called toxin-antitoxin (TA) system that is part of the normal bacterial makeup, may be triggered to make bacteria turn on themselves, providing a valuable target for novel antimicrobial approaches in drug design.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018